Skip to main content
SpringerLink
Log in

Neue Arzneimittel 2009

  • Chapter
Arzneiverordnungs-Report 2010

Zusammenfassung

Die Zahl der jährlich neu eingeführten Arzneimittel hatte in Deutschland 1997 mit 41 neuen Wirkstoffen einen einstweiligen Höhepunkt erreicht, zeigt aber seitdem einen generell rückläufigen Trend (Abbildung 2.1). Eine ähnliche Entwicklung ist auch weltweit zu beobachten (Taylor 2003). Nach einem Tiefpunkt der Neueinführungen im Jahre 2003 stieg die Zahl der neu in die Therapie eingeführten Wirkstoffe in den vergangenen Jahren wieder an und erreichte etwa den Durchschnitt der letzten zehn Jahre. Die Arzneimittel mit neuen Wirkstoffen werden seit 1987 im Arzneiverordnungs-Report mit den Bewertungen von Fricke und Klaus (siehe Fricke 2000) tabellarisch dargestellt. Seit dem Jahr 2000 verfassen wir zusätzlich kurze Charakterisierungen der einzelnen neuen Wirkstoffe und geben Empfehlungen zu ihrer Anwendung.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A (2008): Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 9: 52.

    PubMed  Google Scholar 

  • Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH (2005): The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 111: 3051–3057.

    PubMed  Google Scholar 

  • Bachner M, De Santis M (2008): Vinflunine in the treatment of bladder cancer. Ther Clin Risk Manag 4: 1243–1253.

    CAS  PubMed  Google Scholar 

  • Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Morsli N, Salhi Y, Culine S, von der Maase H (2009): Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27): 4454–4461.

    CAS  PubMed  Google Scholar 

  • Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL (2002): Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 301: 95–102.

    CAS  PubMed  Google Scholar 

  • Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group (2009): Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374: 39–47.

    CAS  PubMed  Google Scholar 

  • Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL (2009): Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113: 2161–2171.

    CAS  PubMed  Google Scholar 

  • Buvat J, Tesfaye F, Rothman M, Rivas DA, Giuliano F (2009): Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 55: 957–967.

    CAS  PubMed  Google Scholar 

  • Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV181-040 Investigators (2009): Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 63: 1395–1406.

    CAS  PubMed  Google Scholar 

  • Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA; Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators (2004a): Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291: 309–316.

    CAS  Google Scholar 

  • Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, Wolff AA; MARISA Investigators (2004b): Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43: 1375–1382.

    CAS  Google Scholar 

  • Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, Borys D, Cleer-bout J, Lommel P, Schuerman L (2009): Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J 28 (4 Suppl): S109–118.

    Google Scholar 

  • Chien AL, Elder JT, Ellis CN (2009): Ustekinumab: a new option in psoriasis therapy. Drugs 69: 1141–1152.

    CAS  PubMed  Google Scholar 

  • Chung M, Kozuch P (2008): Treatment of malignant ascites. Curr Treat Options Oncol 9: 215–233.

    PubMed  Google Scholar 

  • Clark T W, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I (2009): Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 361: 2424–2435.

    CAS  PubMed  Google Scholar 

  • Cohen D, Carter P (2010): WHO and the pandemic flu „conspiracies“. BMJ 2010;340: 1274–1279.

    Google Scholar 

  • Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, Rosenberg M, Higgins J (2006): Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 108: 1089–1097.

    CAS  PubMed  Google Scholar 

  • Cross SA, Scott LJ (2008): Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections. Drugs 68: 2225–2255.

    CAS  PubMed  Google Scholar 

  • Deacon CF (2009): Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag 5: 199–211.

    CAS  PubMed  Google Scholar 

  • Decaux G, Soupart A, Vassart G (2008): Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371: 1624–1632.

    CAS  PubMed  Google Scholar 

  • DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS; Saxagliptin 014 Study Group (2009): The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 32: 1649–1655.

    CAS  PubMed  Google Scholar 

  • Dhillon S, Weber J (2009): Saxagliptin. Drugs 69: 2103–2114.

    CAS  PubMed  Google Scholar 

  • Dineen MK, Tierney DS, Kuzma P, Pentikis HS (2005): An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer. J Clin Pharmacol 45: 1245–1249.

    CAS  PubMed  Google Scholar 

  • DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Richard T. Maziarz RT, Jacobsen E, Nade-manee A, McCarty J, Bridger G, Calandra G (2009a): Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colonystimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-hodgkin’s lymphoma. J Clin Oncol 27: 4767–4673.

    CAS  Google Scholar 

  • DiPersio JF, Stadtmauer EA, Nademanee A, Micallef INM, Stiff PJ, Kaufman JL, Maziarz RL, Hosing C, Früehauf S, Horwitz M, Cooper D, Bridger G, Calandra G, for the 3102 Investigators (2009b): Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113: 5720–5726.

    CAS  Google Scholar 

  • Dixon MB, Lien YH (2008): Tolvaptan and its potential in the treatment of hyponatremia. Ther Clin Risk Manag 4: 1149–1155.

    CAS  PubMed  Google Scholar 

  • Drucker DJ, Nauck MA (2006): The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696--1705.

    CAS  PubMed  Google Scholar 

  • Duggan ST, Plosker GL (2009): Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO]. Drugs 69: 115–122.

    CAS  PubMed  Google Scholar 

  • Editorial (2003): The statin wars: why AstraZeneca must retreat. Lancet 362: 1341.

    Google Scholar 

  • Elger C, Halász P, Maia J., Almeida L, Soares-da-Silva P (2009): Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partialonset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 50, 454–463.

    CAS  PubMed  Google Scholar 

  • Emery P, Keystone E, Tony H P, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J (2008): IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67: 1516–1523.

    CAS  PubMed  Google Scholar 

  • Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU (2009): Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60: 2272–2283.

    CAS  PubMed  Google Scholar 

  • European Medicines Agency (2008): Assessment Report for Mycamine. Internet: www.emea.europa.eu/humandocs/PDFs/EPAR/mycamine/H-734-en6.pdf

  • European Medicines Agency (2009a): Assessment Report for Valdoxane. Internet: www.emea.europa.eu/humandocs/PDFs/EPAR/valdoxan/H-915-en6.pdf

  • European Medicines Agency (2009b): Assessment Report for Ilaris. Internet: www.emea.europa.eu/humandocs/PDFs/EPAR/ilaris/H-1109-en6.pdf

  • European Medicines Agency (2009c): Assessment Report for Removab. Internet: www.emea.europa.eu/humandocs/PDFs/EPAR/removab/H-972-en6.pdf

  • European Medicines Agency (2009d): Assessment Report for Biopoin. Internet: www. ema.europa.eu/humandocs/PDFs/EPAR/biopoin/H-1036-en6.pdf

  • European Medicines Agency (2009e): Assessment Report for Silapo. Internet: www.ema.europa.eu/humandocs/PDFs/EPAR/silapo/H-760-en6.pdf

  • European Medicines Agency (2009f): Assessment Report for Vedrop. Internet: www.emea.europa.eu/humandocs/PDFs/EPAR/vedrop/H-920-en6.pdf

  • European Medicines Agency (2009g): Assessment Report for Ellaone. Internet: www.emea.europa.eu/humandocs/PDFs/EPAR/ellaone/H-1027-en6.pdf

  • European Medicines Agency (2009h): Assessment Report for Stelara. Internet: www. emea.europa.eu/humandocs/PDFs/EPAR/stelara/H-958-en6.pdf

  • Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-Loiseau H; Intergroupe Francophone du Myélome (2007): Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370: 1209–1218.

    CAS  PubMed  Google Scholar 

  • Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae D W, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich R P, Gottlow M, Johnsson E, Zannad F; AURORA Study Group (2009): Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395–13407.

    PubMed  Google Scholar 

  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group (2009): Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10: 223–232.

    CAS  PubMed  Google Scholar 

  • Food and Drug Administration (2005): FDA Alert 6/2005 for Healthcare Professionals: Gefitinib (marketed as Iressa). Internet: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm126182.pdf

  • Frampton JE, Lyseng-Williamson KA (2009): Romiplostim. Drugs 69: 307–317.

    CAS  PubMed  Google Scholar 

  • Fricke U (2000): Arzneimittelinnovationen – Neue Wirkstoffe: 1978–1999. Eine Bestandsaufnahme. In: Klauber J, Schröder H, Selke GW (Hrsg): Innovation im Arzneimittelmarkt, Springer-Verlag, Berlin-Heidelberg-New York, pp. 85–97.

    Google Scholar 

  • Fricke U (2010): Neue Arzneimittel des Jahres 2009. Arzneiverordnung in der Praxis 37: 35–37.

    Google Scholar 

  • Gadola SD (2009): Interleukin-1-Zytokine, Inflammasome, NOD-Signalosome und Autoinflammation. Z Rheumatol 68: 712–719.

    CAS  PubMed  Google Scholar 

  • Gemeinsamer Bundesausschuss (2008): Therapiehinweis zu Exenatide. Internet: www.g-ba.de/downloads/39-261-736/2008-10-16-AMR4-Exenatide_ BAnz.pdf

  • Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ(2008): Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58: 2968–2980.

    CAS  PubMed  Google Scholar 

  • Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P; BIA-2093-303 Investigators Study Group (2009): Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 120: 281–287.

    CAS  PubMed  Google Scholar 

  • Gissi-HF Investigators (2008): Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372: 1231–1239.

    Google Scholar 

  • Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL (2009): Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 361: 2405–2413.

    CAS  PubMed  Google Scholar 

  • Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997): International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079–2088.

    CAS  PubMed  Google Scholar 

  • Gross P, Marczewski T, Herbrig K (2009): The vaptans ante portas: a status report. Nephrol Dial Transplant 24: 1371–1373.

    PubMed  Google Scholar 

  • Heiss MM, Ströhlein MA, Jäger M, Kimmig R, Burges A, Schoberth A, Jauch K W, Schildberg F W, Lindhofer H (2005): Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 117: 435–443.

    CAS  PubMed  Google Scholar 

  • Hicks LK, Haynes AE, Reece DE, Walker IR, Herst JA, Meyer RM, Imrie K; Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence-based Care (2008): A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 34: 442–452.

    CAS  PubMed  Google Scholar 

  • Hollander P, Li J, Allen E, Chen R; CV181-013 Investigators (2009): Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 94: 4810–4819.

    CAS  PubMed  Google Scholar 

  • Inman RD, Davis JC Jr, Heijde D, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J (2008): Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58: 3402–3412.

    CAS  PubMed  Google Scholar 

  • Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE (2009): Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks. Eur Urol 55: 62–75.

    PubMed  Google Scholar 

  • Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; CV181-039 Investigators (2009): Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 11: 611–622.

    CAS  PubMed  Google Scholar 

  • Jelinek T (2002): Japan Enzephalitis. Dtsch Med Wochenschr 127: 1155–1156.

    PubMed  Google Scholar 

  • Jocham D, Doehn C (2009): Words of wisdom. Re: the efficacy and safety of degarelix: a 12-month, comparative, randomized, open- label, parallel-group phase III study in patients with prostate cancer. Eur Urol 55: 1488–1489.

    PubMed  Google Scholar 

  • Jönsson B, Kobelt G, Smolen J (2008): The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ 8: Suppl 2: S61–86.

    Google Scholar 

  • Kassenärztliche Bundesvereinigung (2010): Agomelatin. Wirkstoff aktuell, Ausgabe 05/2010 Interenet: www.akdae.de/Arzneimitteltherapie/WA/Archiv/Agomelatin.pdf

  • Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A (2009): Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60: 976–986.

    CAS  PubMed  Google Scholar 

  • Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU; GO-FORWARD Study (2009): Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 68: 789–796.

    CAS  PubMed  Google Scholar 

  • Keystone E, Heijde D, Mason D Jr, Landewé R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K (2008): Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, doubleblind, placebo-controlled, parallel-group study. Arthritis Rheum 58: 3319–3329.

    CAS  PubMed  Google Scholar 

  • Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers M V, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY (2008): Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809–1818.

    CAS  PubMed  Google Scholar 

  • Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group (2007): Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357: 2248–2261.

    CAS  PubMed  Google Scholar 

  • Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH (2008): The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102: 1531–1589.

    CAS  PubMed  Google Scholar 

  • Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni A P, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators (2007): Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297: 1319–1331.

    CAS  PubMed  Google Scholar 

  • Kothé B, Kentenich H (2008): Was man zur „Pille danach“ wissen sollte. Dtsch Ärztebl 105: A992–A994.

    Google Scholar 

  • Krause G, Gilsdorf A, Becker J, Bradt K, Dreweck C, Gärtner B, Löwer J, Marcic A, Nicoll A, Pott E, Schaade L, Schoeller A, Stollorz V, Träder C, Razum O (2010): Erster Erfahrungsaustausch zur H1N1-Pandemie in Deutschland 2009/2010. Bericht über einen Workshop am 22. und 23. März 2010 in Berlin. Bundesgesundheitsbl 53: 510–519.

    CAS  Google Scholar 

  • Kuehn BM (2009): H1N1 Vaccine. JAMA 302: 375.

    CAS  Google Scholar 

  • Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA; Micafungin Invasive Candidiasis Working Group (2007): Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369: 1519–1527.

    CAS  PubMed  Google Scholar 

  • Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL (2008): Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371: 395–403.

    CAS  PubMed  Google Scholar 

  • Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN; Canakinumab in CAPS Study Group (2009): Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360: 2416–2425.

    CAS  PubMed  Google Scholar 

  • Lemoine P, Guilleminault C, Alvarez E (2007): Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 68: 1723–1732.

    CAS  PubMed  Google Scholar 

  • Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators (2008): Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665–1674.

    CAS  PubMed  Google Scholar 

  • Levy HL, Milanowski A, Chakrapani A, Cleary M, Lee P, Trefz FK, Whitley CB, Feillet F, Feigenbaum AS, Bebchuk JD, Christ-Schmidt H, Dorenbaum A; Sapropterin Research Group (2007): Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenyl-ketonuria: a phase III randomised placebo-controlled study. Lancet 370: 504–510.

    CAS  PubMed  Google Scholar 

  • Lôo H, Hale A, D’haenen H (2002): Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychophar-macol 17: 239–247.

    Google Scholar 

  • Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL (2008): Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300: 173–181.

    CAS  PubMed  Google Scholar 

  • Marks R, Finke J (2006): Die Bedeutung der Stammzelltherapie in der Hämatologie und Onkologie. Internist (Berl) 47: 467–478.

    CAS  Google Scholar 

  • McCormack PL, Robinson DM (2009): Eslicarbazepine acetate. CNS Drugs 23: 71–79.

    CAS  PubMed  Google Scholar 

  • McKenney JM (2005): Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health Syst Pharm 62: 1033–1047.

    CAS  PubMed  Google Scholar 

  • Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS (2009): Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360: 354–362.

    CAS  PubMed  Google Scholar 

  • Mima T, Nishimoto N (2009): Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol 21: 224–230.

    CAS  PubMed  Google Scholar 

  • Modi NB, Dresser MJ, Simon M, Lin D, Desai D, Gupta S (2006): Single- and multipledose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 46: 301–309.

    CAS  PubMed  Google Scholar 

  • Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009): Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947–957.

    CAS  PubMed  Google Scholar 

  • Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008): Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83: 584–594.

    PubMed  Google Scholar 

  • Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald E; MERLIN-TIMI 36 Trial Investigators (2007): Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 297: 1775–1783.

    CAS  PubMed  Google Scholar 

  • Nash DT, Nash SD (2008): Ranolazine for chronic stable angina. Lancet 372: 1335–1341.

    CAS  PubMed  Google Scholar 

  • Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR; LEAD-2 Study Group (2009): Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32: 84–90.

    CAS  PubMed  Google Scholar 

  • NN (2009a): Ranolazine: new drug. Stable angina: not worth the risk. Prescrire Int 18: 148–151.

    Google Scholar 

  • NN (2009b): Tocilizumab: new drug. Rheumatoid arthritis: another ‘mab’, no therapeutic advantage. Prescrire Int 18: 198–201.

    Google Scholar 

  • NN (2009c): Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients. Prescrire Int 18: 202–204.

    Google Scholar 

  • O‘Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD (2009): Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374: 989–997.

    PubMed  Google Scholar 

  • Oldfield V, Dhillon S, Plosker GL (2009): Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs. 69: 609–632.

    CAS  PubMed  Google Scholar 

  • Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P, Boccadoro M; Italian Multiple Myeloma Network, GIMEMA (2006): Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367: 825–831.

    CAS  PubMed  Google Scholar 

  • Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators (2008): Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371: 1675–1684.

    CAS  PubMed  Google Scholar 

  • Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN (2007): Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45: 883–893.

    CAS  PubMed  Google Scholar 

  • Patel RV, Clark LN, Lebwohl M, Weinberg JM (2009): Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 60: 1001–1017.

    PubMed  Google Scholar 

  • Porst H (2009): Der vorzeitige Samenerguss (Ejaculatio praecox). Urologe A 48: 663–674.

    CAS  PubMed  Google Scholar 

  • Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels J P, Schuerman (2006): Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367: 740–748.

    CAS  PubMed  Google Scholar 

  • Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, Miloslavsky M, Kell S; Dapoxetine Study Group (2006): Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 368: 929–937.

    CAS  PubMed  Google Scholar 

  • Punt CJ, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones D, Dethling J, Colman J, Coward L, MacGregor S (2002): Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 360: 671–677.

    CAS  PubMed  Google Scholar 

  • Reissmann T, Schally AV, Bouchard P, Riethmiiller H, Engel J (2000): The LHRH antagonist cetrorelix: a review. Hum Reprod Update 6: 322–331.

    CAS  PubMed  Google Scholar 

  • Richter-Kuhlmann E, Meißner M, Sigmund-Schultze N, Zylka-Menhorn V (2009): Entscheidungshilfen für die Impfung. Dtsch Ärztebl 106: A2180–A2182.

    Google Scholar 

  • Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group (2008): Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207.

    CAS  PubMed  Google Scholar 

  • Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J and the German Cancer Aid 17-1A Study Group (1994): Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet 343: 1177–1183.

    PubMed  Google Scholar 

  • Robert Koch-Institut und Gesellschaft der epidemiologischen Krebsregister in Deutschland (2010): Krebs in Deutschland 2005/2006. Häufigkeiten und Trends, 7. Ausgabe: Internet: www.rki.de/cln_169/nn_205770/DE/Content/GBE/Gesund-heitsberichterstattung/GBEDownloadsB/KID2010,templateId=raw,property=publi cationFile.pdf/KI

  • Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators (2009): Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 25: 2401–2411.

    CAS  PubMed  Google Scholar 

  • Rukazenkov Y, Speake G, Marshall G, Anderton J, Davies BR, Wilkinson RW, Mark Hickinson D, Swaisland A (2009): Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? Anticancer Drugs 20: 856–866.

    CAS  PubMed  Google Scholar 

  • Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R; on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group (2009): Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52: 2046–2055.

    CAS  PubMed  Google Scholar 

  • Sanford M, Keating GM (2009): Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia. Drugs 69: 461–476.

    CAS  PubMed  Google Scholar 

  • Schlegel PN; Histrelin Study Group (2006): Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. J Urol 175: 1353–1358.

    CAS  PubMed  Google Scholar 

  • Schneider M, Lelgemann M, Abholz HH, Caratti R, Flügge C, Jäniche H, Kunz R, Krüger K, Rehart S, Specker C (2007): Interdisziplinäre Leitlinie: Management der frühen rheumatoiden Arthritis. 2. Auflage. Internet: http://dgrh.de/fileadmin/media/Qualitaetssicherung/Leitlinien/gesamt.pdf

  • Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators (2006): Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355: 2099–2112.

    CAS  PubMed  Google Scholar 

  • Schuller E, Jilma B, Voicu V, Golor G, Kollaritsch H, Kaltenböck A, Klade C, Tauber E (2008): Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 26: 4382–4386.

    CAS  PubMed  Google Scholar 

  • Scott DL, Cope A (2009): New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice? Ann Rheum Dis 68: 767–769.

    PubMed  Google Scholar 

  • Scott DL, Kingsley GH (2006): Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355: 704–712.

    CAS  PubMed  Google Scholar 

  • Serebruany V, Shalito I, Kopyleva O (2009): Prasugrel development – claims and achievements. Thromb Haemost 101: 14–22.

    CAS  PubMed  Google Scholar 

  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group (2005): Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132.

    CAS  PubMed  Google Scholar 

  • Siddiqui MA, Scott LJ (2005): Azacitidine: in myelodysplastic syndromes. Drugs 65: 1781–1789.

    CAS  PubMed  Google Scholar 

  • Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF (2002): Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20: 2429–2440.

    CAS  PubMed  Google Scholar 

  • Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999): Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565–1571.

    CAS  PubMed  Google Scholar 

  • Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R; OPTION Investigators (2008): Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371: 987–997.

    CAS  PubMed  Google Scholar 

  • Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU; GO-AFTER study investigators (2009): Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374: 210–121.

    CAS  PubMed  Google Scholar 

  • Sokol RJ, Butler-Simon N, Conner C, Heubi JE, Sinatra FR, Suchy FJ, Heyman MB, Perrault J, Rothbaum RJ, Levy J, et al (1993): Multicenter trial of d-alpha-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis. Gastroenterology. 104: 1727–1735.

    CAS  PubMed  Google Scholar 

  • Ständige Impfkommission (2009a): Empfehlung zur Impfung gegen die Neue Influenza A (H1N1). Epidemiologisches Bulletin Nr. 41, 403–426.

    Google Scholar 

  • Ständige Impfkommission (2009b): Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2009. Internet: www.rki.de/cln_151/nn_1493664/DE/Content/Infekt/EpidBull/Archiv/2009/30__09,templateId=raw,pr operty=publicationFile.pdf/30_09.pdf

  • Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L; ERICA Investigators (2006): Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 48: 566–575.

    CAS  PubMed  Google Scholar 

  • Tang J W, Shetty N, Lam TT (2010): Features of the new pandemic influenza A/ H1N1/2009 virus: virology, epidemiology, clinical and public health aspects. Curr Opin Pulm Med 16: 235–241.

    PubMed  Google Scholar 

  • Task Force on Postovulatory Methods of Fertility Regulation (1998): Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 352: 428–433.

    Google Scholar 

  • Tauber E, Kollaritsch H, Korinek M, Rendi-Wagner P, Jilma B, Firbas C, Schranz S, Jong E, Klingler A, Dewasthaly S, Klade CS (2007): Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 370: 1847–1853.

    CAS  PubMed  Google Scholar 

  • Taylor D (2003): Fewer new drugs from the pharmaceutical industry. Brit Med J 326: 408–409.

    PubMed  Google Scholar 

  • Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K (2005): Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527–1537.

    CAS  PubMed  Google Scholar 

  • Trefz FK, Burton BK, Longo N, Casanova MM, Gruskin DJ, Dorenbaum A, Kakkis ED, Crombez EA, Grange DK, Harmatz P, Lipson MH, Milanowski A, Randolph LM, Vockley J, Whitley CB, Wolff JA, Bebchuk J, Christ-Schmidt H, Hennermann JB; Sapropterin Study Group (2009): Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr 154: 700–707.

    CAS  PubMed  Google Scholar 

  • Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène JP, Lommel P, Dieussaert I, Schuerman L (2009): Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 28 (4 Suppl): S66–76.

    Google Scholar 

  • von Hertzen H, Piaggio G, Ding J, Chen J, Song S, Bártfai G, Ng E, Gemzell-Danielsson K, Oyunbileg A, Wu S, Cheng W, Lüdicke F, Pretnar-Darovec A, Kirkman R, Mittal S, Khomassuridze A, Apter D, Peregoudov A; WHO Research Group on Post-ovulatory Methods of Fertility Regulation (2002): Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 360: 1803–1810.

    Google Scholar 

  • Wagstaff AJ (2009): Plerixafor. In patients with Non-Hodgkin’s lymphoma or multiple myeloma. Drugs 69: 319–326.

    CAS  PubMed  Google Scholar 

  • Waldinger MD (2007): Premature ejaculation: definition and drug treatment. Drugs 67: 547–568.

    CAS  PubMed  Google Scholar 

  • Wallentin L (2009): P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 30: 1964–1977.

    CAS  PubMed  Google Scholar 

  • WHO Collaborating Centre for Drug Statistics Methodology (2010): Anatomischtherapeutisch-chemischer (ATC) Index mit definierten Tagesdosen (DDD). Oslo. Internet: www.whocc.no/atcddd

  • Winkler A, Rath P (1999): Anwendungsbereiche von RU 486 in Gynäkologie und Geburtshilfe. Dtsch Ärztebl 96: A1962–A1967.

    Google Scholar 

  • Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators (2007a): Prasugrel versus clopi-dogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001–2015.

    CAS  Google Scholar 

  • Wiviott SD, Trenk D, Frelinger AL, O‘Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E; PRINCIPLE-TIMI 44 Investigators (2007b): Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116: 2923–2932.

    CAS  Google Scholar 

  • World Health Organization (2009): DG Statement following the meeting of the Emergency Committee. Internet: www.WHO.int/csr/don/2009_07_03/en/index.html

  • Zylka-Menhorn V (2010): Neue Influenza: Kritischer Rückblick mit wegweisender Vorausschau. Dtsch Ärztebl 107: A850–A855.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmakologie, Universität zu Köln, Gleueler Straße 24, 50924, Köln

    Prof. Dr. rer. nat. Uwe Fricke

  2. Pharmakologisches Institut, der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. rer. nat. Uwe Fricke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK Schleswig-Holstein, Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Fricke, U., Schwabe, U. (2010). Neue Arzneimittel 2009. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2010. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13380-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-13380-0_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-13379-4

  • Online ISBN: 978-3-642-13380-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation